Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
The FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults, expanding the drug's existing indication for pharmacologically-induced mydriasis. Viatris holds exclusive U.S. commercialization rights via a global licensing agreement with Opus Genetics and is exploring a U.S. partner to commercialize the presbyopia indication.
Key figures
- Drug Name
- RYZUMVI (phentolamine ophthalmic solution 0.75%)
- New Indication
- presbyopia in adults
- Existing Indication
- pharmacologically-induced mydriasis
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.